Group 1 - The article does not provide any specific content or key points related to a company or industry [1]

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the commencement of a proposed underwritten public offering, subject to market and other conditions, to issue and sell $500 million of American depositary shares (ADSs), each representing three ordinary shares, or for certain investors that so choose, in ...

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points on Monday.The Dow traded down 0.46% to 47,733.58 while the NASDAQ fell 0.32% to 23,501.92. The S&P 500 also fell, dropping, 0.46% to 6,838.69.Check This Out: Top 3 Materials Stocks That Are Preparing To Pump In Q4Leading and Lagging SectorsInformation technology shares jumped by 0.6% on Monday.In trading on Monday, communication services stocks fell by 2.1%.Top HeadlineThe one-year-ahead median inflation e ...

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points on Monday.The Dow traded down 0.46% to 47,733.58 while the NASDAQ fell 0.32% to 23,501.92. The S&P 500 also fell, dropping, 0.46% to 6,838.69.Check This Out: Top 3 Materials Stocks That Are Preparing To Pump In Q4Leading and Lagging SectorsInformation technology shares jumped by 0.6% on Monday.In trading on Monday, communication services stocks fell by 2.1%.Top HeadlineThe one-year-ahead median inflation e ...

Group 1 - U.S. stocks experienced a decline, with the Dow Jones falling over 200 points on Monday [1] - Paramount Skydance Corporation launched an all-cash tender offer to acquire Warner Bros. Discovery, Inc. for $30 per share, valuing the company at $108.4 billion [1] - Paramount aims to create a scaled Hollywood leader by merging with Warner Bros. [1] Group 2 - Paramount Skydance shares increased by 9.8% to $14.68 on Monday [2] - Other notable stocks that gained include Wave Life Sciences Ltd., which rose 129.1% to $17.16 after positive interim Phase 1 data for its obesity drug [4] - Structure Therapeutics Inc. saw a gain of 100.5% to $69.30 following the announcement of topline data from its clinical program for obesity treatment [4] Group 3 - Fulcrum Therapeutics, Inc. shares rose 62.3% to $14.44 after reporting initial results from its Phase 1b trial for sickle cell disease [4] - Kymera Therapeutics, Inc. gained 51.2% to $100.75 after reporting successful trial results for its KT-621 drug [4] - Confluent, Inc. shares increased by 29.2% to $29.89 after IBM agreed to acquire the company for $31 per share [4]

Structure Therapeutics stock (NASDAQ: GPCR) rocketed above 103% Monday, trading near $70, after the clinical-stage biotech released promising mid-stage results for its oral obesity drug, aleniglipron.... ...

Summary of Structure Therapeutics Conference Call on Eleniglipron Company Overview - **Company**: Structure Therapeutics (NasdaqGM: GPCR) - **Product**: Eleniglipron, an oral small molecule GLP-1 receptor agonist - **Focus**: Chronic weight management and obesity treatment Key Industry Insights - **Obesity Market**: - Current injectable peptides serve approximately 5 million people in the U.S., a small fraction of over 100 million people living with obesity or overweight [5][4] - By 2030, around 1.5 billion people globally are expected to be living with obesity or overweight [5] - **Need for Oral Medications**: - Oral small molecules like Eleniglipron can scale to meet the needs of the global patient population [6] Core Findings from Clinical Trials - **ACCESS Phase 2b Study Results**: - At 36 weeks, patients on Eleniglipron experienced placebo-adjusted weight loss of: - 8.2% (45 mg) - 9.8% (90 mg) - 11.3% (120 mg) [7] - In the exploratory ACCESS 2 study, patients on the 120 mg dose experienced a 14.1% placebo-adjusted weight loss [8] - Higher doses (180 mg and 240 mg) showed even greater weight loss of 14.4% and 15.3%, respectively [8] - No evidence of weight loss plateau beyond 36 weeks [8] - **Safety and Tolerability**: - Overall treatment discontinuation rate due to adverse events was 10.4% [9] - No events of drug-induced liver injury reported among over 500 patients treated [10] - Nausea peaked early in the titration phase but remained below 10% by the end of the study [17][19] - Improved tolerability observed with a lower starting dose of 2.5 mg, showing no treatment discontinuations in the first 10 weeks [34][39] Future Development Plans - **Phase 3 Readiness**: - Structure Therapeutics is preparing to move into Phase 3 trials, with an anticipated mid-2026 first patient in [40] - Plans to initiate Phase 3 studies using a 2.5 mg starting dose based on improved tolerability data [41] - **Combination Therapies**: - Eleniglipron is positioned as a backbone for future oral combination therapies [6] - Structure Therapeutics is also developing amylin-targeted molecules and exploring potential indications beyond obesity [42][43] Market Positioning - **Target Audience**: - Focus on primary care physicians and non-specialists who seek effective, convenient, and accessible treatment options for obesity [41] - **Competitive Advantage**: - Eleniglipron's oral formulation and favorable safety profile position it as a potential best-in-class option in the growing chronic weight management market [41] Upcoming Catalysts - **2026 Milestones**: - End of Phase 2 meeting with the FDA - Top-line results from ongoing studies - Initiation of pivotal Phase 3 studies for Eleniglipron [44][45] Conclusion - Eleniglipron demonstrates significant potential in the obesity treatment landscape, with compelling efficacy and a favorable safety profile, setting the stage for its advancement into Phase 3 clinical trials and broader market introduction.

Aleniglipron Efficacy - In the Phase 2b ACCESS trial, Aleniglipron achieved placebo-adjusted mean weight loss of 82% at 45 mg, 98% at 90 mg, and 113% at 120 mg at 36 weeks[41] - Exploratory ACCESS II study showed placebo-adjusted mean weight loss at 36 weeks of 141% at 120 mg, 144% at 180 mg, and 153% at 240 mg[72] - ACCESS Open Label Extension (OLE) study indicated that weight loss continues to increase in all arms through Week 44, with no evidence of a weight loss plateau[50] Aleniglipron Tolerability and Safety - Phase 2b ACCESS trial showed an overall 104% AE-related treatment discontinuation rate, with GI-related AEs consistent with the GLP-1RA class[41] - In the Exploratory ACCESS II trial, participants who achieved re-randomization experienced no AE-related treatment discontinuations up to the 240 mg dose at week 36[72] - Body Composition study showed improved tolerability with a lower 25 mg starting dose, with no treatment discontinuations due to AEs after a median treatment of approximately 10 weeks[83] - Across all studies with over 500 participants treated up to 44 weeks, there were no events of drug-induced liver injury, off-target safety signals, or QTc prolongation[96] Market Opportunity and Scalability - The overweight and obesity market includes over 800 million people worldwide, with projections of 15 billion people by 2030[14] - The total addressable market for obesity treatments is estimated to be over $100 billion[14] - Oral small molecules like Aleniglipron can scale to meet the needs of the global obesity patient population, offering potential advantages in accessibility and cost compared to injectable peptides[12, 15]

Core Insights - Structure Therapeutics announced that its obesity pill demonstrated an 11.3% reduction in weight during a mid-stage study [1] Company Summary - Structure Therapeutics is focusing on developing treatments for obesity, with recent clinical trial results indicating promising efficacy [1]

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight loss up to 15.3% (35.5 lbs) observed with 240 mg dose in the exploratory ACCESS II study at 36 weeks No adverse event-related treatment discontinuations observed when starting at lower 2.5 mg dose in ACCESS Open Label Extension and Body Composition Study Data comprehensively support and inform advancement to Ph ...